Truncated transposase, transposome system and applications thereof

By truncating the PS transposase and fusing it with a functional peptide, the length and activity of the transposase were optimized, solving the problem of low transposition efficiency of the PS transposase and achieving efficient gene insertion and editing effects.

CN122303184APending Publication Date: 2026-06-30MAXIRNA (SHANGHAI) PHARM CO LTD +2
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Applications(China)
Current Assignee / Owner
MAXIRNA (SHANGHAI) PHARM CO LTD
Filing Date
2024-12-30
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Existing PS transposases have low transposition efficiency, and the natural PS transposon system is insufficient in terms of genome insertion efficiency, making it difficult to meet the needs of efficient gene transfer.

Method used

By deleting amino acids from the C-terminus of PS transposases, truncated transposases were prepared. By combining them with functional peptides such as the leucine zipper domain, the length and activity of the transposases were optimized, thereby improving transposition efficiency. Furthermore, the transposition efficiency was further enhanced through mutants.

Benefits of technology

The transposase length has been shortened, improving transposition efficiency, making it suitable for non-viral vectors, reducing cellular burden, and enhancing transduction efficiency, making it suitable for gene therapy and gene editing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005218572450000131
    Figure BDA0005218572450000131
  • Figure BDA0005218572450000141
    Figure BDA0005218572450000141
  • Figure BDA0005218572450000151
    Figure BDA0005218572450000151
Patent Text Reader

Abstract

The application provides a truncated transposase, a transposon system and application thereof. Compared with a wild-type PS transposase, the truncated transposase lacks 1-50 amino acids at the C terminal of the wild-type PS transposase, preferably 44 amino acids. By deleting the amino acids at the C terminal of the transposase which have less influence on transposition, the length of the transposase is shortened, which is beneficial to the expression of the transposase and the preparation of a fusion protein, so that a transposase or a fusion protein thereof with higher catalytic activity and smaller size is obtained. The application also provides a fusion protein of the transposase, which is preferably fused with a leucine zipper through a linker, and a transposon system comprising the transposase and the transposon, which has great application value in the transgenic industry.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Antibiotic-free microplasmid as well as preparation method and application thereof

    CN118374547A

  • Transposase, transposon, transposon system and application thereof

    CN118480526A

  • Antibiotic-free plasmid production strain and application thereof

    CN121343851A